We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.87B
1-Year Est. Return
205.24%
This Fund
S&P 500
This Quarter
Est. Return
+25.88%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.99B
AUM Growth
+$404M
(+16%)
Cap. Flow
-$138M
Cap. Flow
% of AUM
-4.62%
Top 10 Holdings %
Top 10 Hldgs %
40.51%
Holding
78
New
15
Increased
15
Reduced
16
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$140M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$48M |
| 3 |
ABVX
Abivax
ABVX
|
+$43.8M |
| 4 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$42.2M |
| 5 |
TRML
Tourmaline Bio
TRML
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$136M |
| 2 |
Structure Therapeutics
GPCR
|
+$92.6M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$75.9M |
| 4 |
Immunovant
IMVT
|
+$66.2M |
| 5 |
NovoCure
NVCR
|
+$40.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.33% |
| 2 | Miscellaneous | 4.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Nektar Therapeutics
NKTR
$2.3B
| $10.4M | 0.35% |
1,226,667
| – | – |
|
52
PUT
Prothena Corp
PRTA
$423M
| $9.09M | 0.3% |
250,000
| – | – |
|
53
Relmada Therapeutics
RLMD
$450M
| $8.46M | 0.28% |
2,044,507
-793,311
| -28% | -$2.35M |
|
|
ALLK
54
DELISTED
Allakos
ALLK
| $6.85M | 0.23% |
+2,510,736
| New | +$5.66M |
|
|
SYRS
55
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $6.45M | 0.22% |
828,485
| – | – |
|
56
Protagonist Therapeutics
PTGX
$9.24B
| $6.31M | 0.21% |
+275,201
| New | +$4.82M |
|
|
57
Jazz Pharmaceuticals
JAZZ
$15.8B
| $5.94M | 0.2% |
48,280
-1,089,765
| -96% | -$136M |
|
|
VIGL
58
DELISTED
Vigil Neuroscience
VIGL
| $5.39M | 0.18% |
1,594,931
-172,200
| -10% | -$886K |
|
59
Aligos Therapeutics
ALGS
$31.5M
| $4.05M | 0.14% |
+244,111
| New | +$4.2M |
|
60
GH Research
GHRS
$1.9B
| $2.9M | 0.1% |
499,400
| – | – |
|
61
Acumen Pharmaceuticals
ABOS
$189M
| – | – |
-2,513,044
| Closed | -$10.4M |
|
62
Amylyx Pharmaceuticals
AMLX
$3.64B
| – | – |
-1,259,335
| Closed | -$23.1M |
|
|
ATXS
63
DELISTED
Astria Therapeutics
ATXS
| – | – |
-1,037,873
| Closed | -$7.74M |
|
64
Beam Therapeutics
BEAM
$2.39B
| – | – |
-1,015,641
| Closed | -$24.4M |
|
65
BioNTech
BNTX
$24.1B
| – | – |
-200,000
| Closed | -$21.7M |
|
|
CMPS
66
Compass Pathways
CMPS
$1.91B
| – | – |
-328,424
| Closed | -$2.43M |
|
|
ETNB
67
DELISTED
89bio
ETNB
| – | – |
-91,078
| Closed | -$1.41M |
|
68
Heron Therapeutics
HRTX
$60.3M
| – | – |
-2,086,704
| Closed | -$2.15M |
|
69
Century Therapeutics
IPSC
$337M
| – | – |
-543,008
| Closed | -$1.09M |
|
70
Moderna
MRNA
$58.1B
| – | – |
-200,000
| Closed | -$20.7M |
|
71
Neurocrine Biosciences
NBIX
$15.2B
| – | – |
-300,000
| Closed | -$33.8M |
|
72
Nuvation Bio
NUVB
$2.03B
| – | – |
-7,720,688
| Closed | -$10.3M |
|
73
Novavax
NVAX
$1.54B
| – | – |
-1,000,000
| Closed | -$7.24M |
|
|
74
NovoCure
NVCR
$1.89B
| – | – |
-2,500,000
| Closed | -$40.4M |
|
|
SLRN
75
DELISTED
ACELYRIN
SLRN
| – | – |
-551,289
| Closed | -$5.61M |
|
Similar funds
PFS
EWM
NP
NPT
RCWMU
CA
LIP
CI
Deep Track Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Deep Track Capital held 78 positions worth $2.99B, up 16% from $2.59B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Deep Track Capital withdrew a net $138M in Q4 2023, closing 18 positions and reducing 16 holdings. Its most notable exit was NovoCure, an estimated $40.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Deep Track Capital opened a new position in argenx worth $114M.
- Deep Track Capital's largest Q4 2023 buy was argenx: 300,000 shares worth $114M.
- Deep Track Capital added most to Guardant Health in Q4 2023, an estimated $24.9M increase.
- Deep Track Capital's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $136M.
- Deep Track Capital fully exited NovoCure in Q4 2023, selling an estimated $40.4M.
- Deep Track Capital's ten largest holdings make up 41% of its $2.99B portfolio in Q4 2023.
- Deep Track Capital opened 15 new positions and closed 18 in Q4 2023.
- Deep Track Capital's portfolio value rose 16% quarter-over-quarter to $2.99B.
Based on Deep Track Capital's 13F filing for Q4 2023, filed 14 Feb 2024.